Bristol Myers Squibb Patent-Cliff Exposure & CMS Drug Spending Portfolio
Bristol Myers Squibb (Princeton, NJ): 36 reconciled FDA prescription therapies (85.1% 2025 to 2030 cliff risk), $32.18B 2024 CMS Part D & Medicaid spend, and 101 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Princeton, NJ |
| Reconciled FDA Portfolio Therapies | 36 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 85.1% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $32.18B |
| 2024 Medicare Part D Spend | $29.44B |
| 2024 Medicaid Spend | $2.74B |
| California HCAI SB 17 Filings | 101 WAC filings (max 29.5% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.